Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence

Head and Neck

Volumn 34, Issue 3, 2012, Pages 344-353

  Gan, Chai Phei ^a,b   Hamid, Sharifah ^a   Hor, Seen Yii ^a   Zain, Rosnah Binti ^b   Ismail, Siti Mazlipah ^b   Wan Mustafa, Wan Mahadzir ^c   Teo, Soo Hwang ^a   Saunders, Nicholas ^d   Cheong, Sok Ching ^a,b  

^a Sime Darby Medical Centre   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

head and neck cancer; histone deacetylase inhibitor; senescence; terminal differentiation; valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RETINOIC ACID; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; DRUG SCREENING; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SENESCENCE; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL AGING; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; TRETINOIN; VALPROIC ACID;

EID: 84856493335     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21734     Document Type: Article

References (77)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
3. Chuang SC, Scelo G, Tonita JM, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 2008; 123: 2390-2396.
4. Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer. Oral Oncol 2009; 45: 201-211.
5. Cheung P, Allis CD, Sassone-Corsi P,. Signaling to chromatin through histone modifications. Cell 2000; 103: 263-271.
6. Sakuma T, Uzawa K, Onda T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006; 29: 117-124.
7. Mahlknecht U, Hoelzer D,. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000; 6: 623-644.
8. Cress WD, Seto E,. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1-16. (Pubitemid 30349623)
9. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY,. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009; 45: 610-614.
10. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-5170.
11. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T,. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268: 22429-22435. (Pubitemid 23318291)
12. Marks PA, Richon VM, Breslow R, Rifkind RA,. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483. (Pubitemid 33027900)
13. Marks PA, Richon VM, Rifkind RA,. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-1216. (Pubitemid 30627729)
14. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998; 95: 3003-3007. (Pubitemid 28135844)
15. Saunders N, Dicker A, Popa C, Jones S, Dahler A,. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999; 59: 399-404. (Pubitemid 29048874)
16. Yoshida M, Kijima M, Akita M, Beppu T,. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-17179.
17. Blattmann C, Oertel S, Ehemann V, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010; 78: 237-245.
18. Chinnaiyan P, Cerna D, Burgan WE, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008; 14: 5410-5415.
19. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S,. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007; 30: 1181-1188.
20. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443. (Pubitemid 32298546)
21. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC,. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005; 4: 1912-1922. (Pubitemid 43056974)
22. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP,. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53-61. (Pubitemid 40127644)
23. Schwartz C, Palissot V, Aouali N, et al. Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 2007; 30: 573-582.
24. Shen WT, Wong TS, Chung WY, et al. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 2005; 138: 979-984; discussion 984-985.
25. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP,. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004; 101: 2760-2770. (Pubitemid 39603184)
26. Parsons PG, Hansen C, Fairlie DP, et al. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol 1997; 53: 1719-1724. (Pubitemid 27356102)
27. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG,. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999; 80: 1252-1258. (Pubitemid 29264087)
28. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4: 22.
29. Cheson BD, Zwiebel JA, Dancey J, Murgo A,. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000; 27: 560-577.
30. Gore SD, Carducci MA,. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 2000; 9: 2923-2934.
31. Kramer OH, Göttlicher M, Heinzel T,. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001; 12: 294-300. (Pubitemid 33714220)
32. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK,. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202. (Pubitemid 33741894)
33. Arce C, Pérez-Plasencia C, González-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006; 1: e98.
34. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97: 177-182. (Pubitemid 47057472)
35. Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529-1538. (Pubitemid 47365487)
36. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 1979-1985. (Pubitemid 46972780)
37. Bowden CL, Singh V,. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl 2005; 426: 13-20. (Pubitemid 40604345)
38. Johannessen CU,. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37: 103-110. (Pubitemid 30254142)
39. Tunnicliff G,. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 1999; 50: 347-365. (Pubitemid 29473097)
40. Kaiser M, Zavrski I, Sterz J, et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-251.
41. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-1269. (Pubitemid 39166498)
42. Regan CM,. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res 1985; 347: 394-398. (Pubitemid 16213521)
43. Balbi A, Sottofattori E, Mazzei M, Sannita WG,. Study of bioequivalence of magnesium and sodium valproates. J Pharm Biomed Anal 1991; 9: 317-321.
44. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC,. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982; 19: 315-359. (Pubitemid 13101805)
45. Erlich RB, Rickwood D, Coman WB, Saunders NA, Guminski A,. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009; 63: 381-389.
46. Keen JC, Yan L, Mack KM, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 2003; 81: 177-186. (Pubitemid 37352455)
47. Yu C, Rahmani M, Almenara J, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63: 2118-2126. (Pubitemid 36538615)
48. Zhu WG, Otterson GA,. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 2003; 3: 187-199. (Pubitemid 36512029)
49. Hamid S, Lim KP, Zain RB, et al. Establishment and characterization of Asian oral cancer cell lines as in vitro models to study a disease prevalent in Asia. Int J Mol Med 2007; 19: 453-460.
50. Lee HB, Ho AS, Teo SH,. p53 Status does not affect photodynamic cell killing induced by hypericin. Cancer Chemother Pharmacol 2006; 58: 91-98.
51. Kirstein SL, Atienza JM, Xi B, et al. Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev Technol 2006; 4: 545-553. (Pubitemid 46017398)
52. Cheong SC, Chandramouli GV, Saleh A, et al. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol 2009; 45: 712-719.
53. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999; 5: 2704-2713. (Pubitemid 29493943)
54. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 2004; 10: 1733-1742. (Pubitemid 38435565)
55. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA,. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007; 67: 1099-1110. (Pubitemid 46983339)
56. Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141-1149. (Pubitemid 38198916)
57. Prystowsky MB, Adomako A, Smith RV, et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009; 218: 467-477.
58. Yao J, Duan L, Fan M, Wu X,. NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. Pharmacol Res 2006; 54: 406-413. (Pubitemid 46053815)
59. Kim S, Kang JK, Kim YK, et al. Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 2006; 342: 1168-1173.
60. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J,. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 2002; 20: 97-106.
61. Claus R, Lübbert M,. Epigenetic targets in hematopoietic malignancies. Oncogene 2003; 22: 6489-6496. (Pubitemid 37372329)
62. Kartasova T, van Muijen GN, van Pelt-Heerschap H, van de Putte P,. Novel protein in human epidermal keratinocytes: regulation of expression during differentiation. Mol Cell Biol 1988; 8: 2204-2210.
63. Presland RB, Dale BA,. Epithelial structural proteins of the skin and oral cavity: function in health and disease. Crit Rev Oral Biol Med 2000; 11: 383-408. (Pubitemid 32003253)
64. Rice RH, Green H,. Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: activation of the cross-linking by calcium ions. Cell 1979; 18: 681-694. (Pubitemid 10216994)
65. Watt FM, Green H,. Involucrin synthesis is correlated with cell size in human epidermal cultures. J Cell Biol 1981; 90: 738-742. (Pubitemid 12254932)
66. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB,. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107. (Pubitemid 29036293)
67. Amos B, Lotan R,. Retinoid-sensitive cells and cell lines. Methods Enzymol 1990; 190: 217-225.
68. McBurney MW, Costa S, Pratt MA,. Retinoids and cancer: a basis for differentiation therapy. Cancer Invest 1993; 11: 590-598. (Pubitemid 23281855)
69. Smith MA, Parkinson DR, Cheson BD, Friedman MA,. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-864.
70. Ki Hong W, Lippman SM, Hittelman WN, Lotan R,. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res 1995; 1: 677-686.
71. Lippman SM, Lotan R,. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000; 130 (2S Suppl): 479S-482S. (Pubitemid 30073777)
72. Lotan R,. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-1039. (Pubitemid 26285979)
73. Sirchia SM, Ferguson AT, Sironi E, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000; 19: 1556-1563. (Pubitemid 30175677)
74. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000; 92: 826-832. (Pubitemid 30368039)
75. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM,. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814. (Pubitemid 28099682)
76. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7. (Pubitemid 32095688)
77. Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006; 66: 8903-8911. (Pubitemid 44449209)